Cited by 286Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease

Open access
Kelly, Sarah C., He, Bin, Perez, Sylvia E., Ginsberg, Stephen D., Mufson, Elliott J., Counts, Scott E.·2017·Acta Neuropathologica Communications

Abstract

A major feature of Alzheimer's disease (AD) is the loss of noradrenergic locus coeruleus (LC) projection neurons that mediate attention, memory, and arousal. However, the extent to which the LC projection system degenerates during the initial stages of AD is still under investigation. To address this question, we performed tyrosine hydroxylase (TH) immunohistochemistry and unbiased stereology of noradrenergic LC neurons in tissue harvested postmortem from subjects who died with a clinical diagnosis of no cognitive impairment (NCI), amnestic mild cognitive impairment (aMCI, a putative prodromal AD stage), or mild/moderate AD. Stereologic estimates of total LC neuron number revealed a 30% loss during the transition from NCI to aMCI, with an additional 25% loss of LC neurons in AD. Decreases in noradrenergic LC neuron number were significantly associated with worsening antemortem global cognitive function as well as poorer performance on neuropsychological tests of episodic memory, semantic memory, working memory, perceptual speed, and visuospatial ability. Reduced LC neuron numbers were also associated with increased postmortem neuropathology. To examine the cellular and molecular pathogenic processes underlying LC neurodegeneration in aMCI, we performed single population microarray analysis. These studies revealed significant reductions in select functional classes of mRNAs regulating mitochondrial respiration, redox homeostasis, and neuritic structural plasticity in neurons accessed from both aMCI and AD subjects compared to NCI. Specific gene expression levels within these functional classes were also associated with global cognitive deterioration and neuropathological burden. Taken together, these observations suggest that noradrenergic LC cellular and molecular pathology is a prominent feature of prodromal disease that contributes to cognitive dysfunction. Moreover, they lend support to a rational basis for targeting LC neuroprotection as a disease modifying strategy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-017-0411-2

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E.
Affiliations
  • Michigan State University (US)
  • Barrow Neurological Institute (US)
  • Nathan Kline Institute for Psychiatric Research (US)
  • Trinity Health Grand Rapids (US)
Corresponding author
Counts, Scott E.
Venue
Acta Neuropathologica Communications
Published
2017-01-21
Volume
5
Issue
1
Pages
8-8
ISSN
2051-5960 (ISSN-L)
OpenAlex
W2579788133
Cited by
286
References
129
Citations by year
2026: 22 · 2025: 28 · 2024: 41 · 2023: 35 · 2022: 34 · 2021: 48 · 2020: 27 · 2019: 26 · 2018: 12 · 2017: 12 · 2016: 1
FWCI
15.57
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (AG043375, AG042146)
  • Saint Mary's Foundation
  • Barrow and Beyond
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, locus coeruleus, noradrenergic neurons, neuronal loss, amnestic mild cognitive impairment, prodromal Alzheimer's disease, tyrosine hydroxylase, stereology, gene expression, mitochondrial respiration, redox homeostasis, cognitive decline, postmortem neuropathology, neuroprotection
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cell Count, Female, Humans, Immunohistochemistry, Locus Coeruleus, Longitudinal Studies, Male, Neurons, Neuropsychological Tests, RNA, Messenger, Tyrosine 3-Monooxygenase, Gene Expression, Disease Progression, Microarray Analysis, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review